{"nctId":"NCT00891202","briefTitle":"A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)","startDateStruct":{"date":"2009-11"},"conditions":["Gaucher Disease, Type 1"],"count":40,"armGroups":[{"label":"Active","type":"EXPERIMENTAL","interventionNames":["Drug: Eliglustat tartrate"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Eliglustat tartrate","otherNames":["Genz-112638"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The participant (and/or their parent/legal guardian) was willing and able to provide signed informed consent prior to any study-related procedures to be performed;\n* The participant was at least 16 years old at the time of randomization;\n* The participant had a confirmed diagnosis of Gaucher disease Type 1;\n* Female participants of childbearing potential must had a documented negative pregnancy test prior to dosing. In addition all female participants of childbearing potential must use a medically accepted form of contraception throughout the study.\n\nExclusion Criteria:\n\n* The participant has had a partial or total splenectomy;\n* The participant had received pharmacological chaperones or miglustat within 6 months prior to randomization;\n* The participant had received enzyme replacement therapy within 9 months prior to randomization;\n* The participant had Type 2 or 3 Gaucher disease or was suspected of having Type 3 Gaucher disease;\n* The participant had any clinically significant disease, other than Gaucher disease, including cardiovascular, renal, hepatic, gastrointestinal (GI), pulmonary, neurologic, endocrine, metabolic, (for example, hypokalemia, hypomagnesemia), or psychiatric disease, other medical conditions, or serious intercurrent illness that might confound the study results, or, on the opinion of the investigator, might preclude participation in the study;\n* The participant had tested positive for the human immunodeficiency virus (HIV) antibody, Hepatitis C antibody, or Hepatitis B surface antigen;\n* The participant had received an investigational product within 30 days prior to randomization;\n* The participant was pregnant or lactating.","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"PAP: Percent Change From Baseline in Spleen Volume (in Multiples of Normal [MN]) at Week 39 of the Primary Analysis Period With Eliglustat Tartrate Treatment as Compared to Placebo","description":"Percent change in spleen volume = (\\[spleen volume at Week 39 minus spleen volume at baseline\\] divided by \\[spleen volume at baseline\\]) multiplied by 100, where all volumes are in MN.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.77","spread":"2.37"},{"groupId":"OG001","value":"2.26","spread":"2.37"}]}]}]},{"type":"SECONDARY","title":"PAP: Hemoglobin Level","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.05","spread":"1.816"},{"groupId":"OG001","value":"12.75","spread":"1.629"}]}]}]},{"type":"SECONDARY","title":"PAP: Absolute Change From Baseline in Hemoglobin Level at Week 39","description":"Absolute change = hemoglobin level at Week 39 minus hemoglobin level at baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.69","spread":"0.23"},{"groupId":"OG001","value":"-0.54","spread":"0.23"}]}]}]},{"type":"SECONDARY","title":"PAP: Percent Change From Baseline in Liver Volume (in MN) at Week 39","description":"Percent change in liver volume = (\\[liver volume at Week 39 minus liver volume at baseline\\] divided by \\[liver volume at baseline\\]) multiplied by 100, where all volumes are in MN.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.20","spread":"1.64"},{"groupId":"OG001","value":"1.44","spread":"1.64"}]}]}]},{"type":"SECONDARY","title":"PAP: Percent Change From Baseline in Platelet Counts at Week 39","description":"Percent change in platelet count = (\\[platelet count at Week 39 minus platelet count at baseline\\] divided by \\[platelet count at baseline\\]) multiplied by 100.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.00","spread":"5.95"},{"groupId":"OG001","value":"-9.06","spread":"5.95"}]}]}]},{"type":"SECONDARY","title":"LTTP: Percent Change From Baseline in Spleen Volume (in MN) at Week 234","description":"Percent change in spleen volume = (\\[spleen volume at Week 234 minus spleen volume at baseline\\] divided by \\[spleen volume at baseline\\]) multiplied by 100, where all volumes are in MN. Baseline values for the original placebo participants refer to Day 1 of LTTP and baseline values for the original eliglustat participants refer to the Day 1 of PAP.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-66.9","spread":"8.45"},{"groupId":"OG001","value":"-64.0","spread":"6.43"}]}]}]},{"type":"SECONDARY","title":"LTTP: Absolute Change From Baseline in Hemoglobin Level at Week 234","description":"Baseline values for the original placebo participants refer to Day 1 of LTTP and baseline values for the original eliglustat participants refer to the Day 1 of PAP.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"0.65"},{"groupId":"OG001","value":"1.9","spread":"1.88"}]}]}]},{"type":"SECONDARY","title":"LTTP: Percent Change From Baseline in Liver Volume (in MN) at Week 234","description":"Percent change in liver volume = (\\[liver volume at Week 234 minus liver volume at baseline\\] divided by \\[liver volume at baseline\\]) multiplied by 100, where all volumes are in MN. Baseline values for the original placebo participants refer to Day 1 of LTTP and baseline values for the original eliglustat participants refer to the Day 1 of PAP.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.3","spread":"11.21"},{"groupId":"OG001","value":"-22.4","spread":"10.77"}]}]}]},{"type":"SECONDARY","title":"LTTP: Percent Change From Baseline in Platelet Counts at Week 234","description":"Percent change in platelet count = (\\[platelet count at Week 234 minus platelet count at baseline\\] divided by \\[platelet count at baseline\\]) multiplied by 100. Baseline values for the original placebo participants refer to Day 1 of LTTP and baseline values for the original eliglustat participants refer to the Day 1 of PAP.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.3","spread":"28.17"},{"groupId":"OG001","value":"100.1","spread":"80.69"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":20},"commonTop":["Headache","Arthralgia","Pain in extremity","Nasopharyngitis","Upper respiratory tract infection"]}}}